Remote monitoring of progression in early Parkinson’s disease: reliability and validity of the Roche PD Mobile Application v2
Remote monitoring of progression in early Parkinson’s disease: reliability and validity of the Roche PD Mobile Application v2
Abstract Digital health technologies (DHTs) enable remote and therefore frequent measurement of motor signs, potentially providing reliable and valid estimates of motor sign severity and progression in Parkinson’s disease (PD). The Roche PD Mobile Application v1 was revised to v2 to include more measures of bradykinesia, and bradyphrenia and speech tests, to optimize suitability for early-stage PD. It was studied in 316 early-stage PD participants who performed daily active tests at home then carried a smartphone and wore a smartwatch throughout the day for passive monitoring (study NCT03100149). Adherence was excellent (96.29%). All pre-specified sensor features exhibited good-to-excellent test-retest reliability (median intraclass correlation coefficient = 0.9), and correlated with corresponding Movement Disorder Society - Unified Parkinson’s Disease Rating Scale items (rho: 0.12–0.71). These findings demonstrate the preliminary reliability and validity of remote at-home quantification of motor sign severity with the Roche PD Mobile Application v2 in individuals with early PD.
Lipsmeier Florian、Boulay Anne、Popp Werner L.、Cheng Wei-Yi、Svoboda Hanno、Pagano Gennaro、Lindemann Michael、Volkova-Volkmar Ekaterina、Postuma Ronald B.、Bamdadian Atieh、Zago Wagner、Zhang Yan Ping、Mollenhauer Brit、Kilchenmann Timothy、Wolf Detlef、Schjodt-Eriksen Jens、Taylor Kirsten I.
Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Idorisa Pharmaceuticals LtdRoche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Department of Neurology, McGill University, Montreal General HospitalRoche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Prothena Biosciences IncRoche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Paracelsus-Elena-Klinik||Department of Neurology, University Medical Center G?ttingenRoche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
神经病学、精神病学医学研究方法药学
digital biomarkersParkinson’s diseaseremote patient monitoringclinical studywearable technologytremorbradykinesia
Lipsmeier Florian,Boulay Anne,Popp Werner L.,Cheng Wei-Yi,Svoboda Hanno,Pagano Gennaro,Lindemann Michael,Volkova-Volkmar Ekaterina,Postuma Ronald B.,Bamdadian Atieh,Zago Wagner,Zhang Yan Ping,Mollenhauer Brit,Kilchenmann Timothy,Wolf Detlef,Schjodt-Eriksen Jens,Taylor Kirsten I..Remote monitoring of progression in early Parkinson’s disease: reliability and validity of the Roche PD Mobile Application v2[EB/OL].(2025-03-28)[2025-06-12].https://www.medrxiv.org/content/10.1101/2021.10.07.21264414.点此复制
评论